From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Clinical data
Trade namesUbrelvy
Other namesMK-1602
License data
Routes of
By mouth
ATC code
  • none
Legal status
Legal status
  • (6S)-N-[(3S,5S,6R)-6-Methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide
CAS Number
PubChem CID
PubChem SID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass549.554 g·mol−1
3D model (JSmol)
  • CC1C(CC(C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(CC4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=CC=CC=C6
  • InChI=1S/C29H26F3N5O3/c1-16-20(17-6-3-2-4-7-17)11-22(26(39)37(16)15-29(30,31)32)35-25(38)19-10-18-12-28(13-23(18)34-14-19)21-8-5-9-33-24(21)36-27(28)40/h2-10,14,16,20,22H,11-13,15H2,1H3,(H,35,38)(H,33,36,40)/t16-,20-,22+,28+/m1/s1

Ubrogepant, sold under the brand name Ubrelvy, is a medication used for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults.[1][2] It is not indicated for the preventive treatment of migraine.[2] It is the first drug[3] in the class of oral calcitonin gene-related peptide receptor antagonists approved for the acute treatment of migraine.[2]

The most common side effects are nausea, tiredness and dry mouth.[2] Ubrogepant is contraindicated for co-administration with strong CYP3A4 inhibitors.[2]

It is a small-molecule calcitonin gene-related peptide receptor antagonist.[4][5]


The effectiveness of ubrogepant for the acute treatment of migraine was demonstrated in two randomized, double-blind, placebo-controlled trials.[2] In these studies, 1,439 adult patients with a history of migraine, with and without aura, received the approved doses of ubrogepant to treat an ongoing migraine.[2] In both studies, the percentages of patients achieving pain freedom two hours after treatment (defined as a reduction in headache severity from moderate or severe pain to no pain) and whose most bothersome migraine symptom (nausea, light sensitivity or sound sensitivity) stopped two hours after treatment were significantly greater among patients receiving ubrogepant (19–21% depending on the dose) compared to those receiving placebo (12%).[2][6] Patients were allowed to take their usual acute treatment of migraine at least two hours after taking ubrogepant.[2] 23% of patients were taking a preventive medication for migraine.[2]

In December 2019, the U.S. Food and Drug Administration approved Ubrelvy produced by Allergan USA, Inc. for treatment of migraine after onset.[2][7]


  1. ^ a b "Ubrelvy- ubrogepant tablet". DailyMed. Retrieved 4 June 2021.
  2. ^ a b c d e f g h i j k "FDA approves new treatment for adults with migraine". U.S. Food and Drug Administration (FDA) (Press release). 23 December 2019. Archived from the original on 23 December 2019. Retrieved 23 December 2019. This article incorporates text from this source, which is in the public domain.
  3. ^ "What You Need to Know About Ubrelvy, First Acute CGRP Med Approved". Migraine Again. 28 January 2020. Retrieved 3 June 2021.
  4. ^ Tfelt-Hansen P, Olesen J (April 2011). "Possible site of action of CGRP antagonists in migraine". Cephalalgia. 31 (6): 748–50. doi:10.1177/0333102411398403. PMID 21383046. S2CID 22049557.
  5. ^ Spreitzer H (22 May 2018). "Neue Wirkstoffe: Ubrogepant". Österreichische Apotheker-Zeitung (in German) (11/2018).
  6. ^ Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, Szegedi A (December 2019). "Ubrogepant for the Treatment of Migraine". The New England Journal of Medicine. 381 (23): 2230–2241. doi:10.1056/NEJMoa1813049. PMID 31800988.
  7. ^ Maddipatla M (23 December 2019). "Allergan's acute migraine treatment wins U.S. FDA approval". Reuters. Retrieved 24 December 2019.

External links[edit]